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Feline Heartworm Disease
Frank Smith, D.V.M.
Pet owners and veterinarians have long 
been aware of the problem of heartworms in 
dogs. Recently the problem is being rec­
ognized in cats. The increase in reported 
cases may be due to a heightened awareness 
of veterinarians to this problem in the 
cat; an increase in the number of necrop­
sies performed each year; or a growing 
number of mosquitoes that will parasitize 
cats. Unfortunately for cats, this dis­
ease can be very difficult to diagnose and 
complications can be associated with the 
treatment of the disease.
The dog appears to be the natural host 
of the heartworm. Although cats do get 
the disease, they are much more resistant 
to infection than the dog and hence have 
fewer worms when infected. Studies have 
shown that 1-25% of third stage larva will 
mature to adults in cats, whereas 40-90% 
will mature to adults in dogs. The worms 
mature more slowly in the cat and the pa­
tency period is shorter. Microfilaremia 
is less common in the cat, being present 
in only 20% of the the heartworm-positive 
cats. Causes of amicrofilaremia include 
unisex infections, sterile females, imma­
ture females, ectopic infections, and re­
moval of microfilaria by the reticuloendo­
thelial system in the lungs. The height­
ened immune reaction in cats results in 
more severe pulmonary damage per worm in 
cats than in dogs. The adult heartworms 
live about two years in cats versus five 
years in dogs.
Pathology
Cardiopulmonary damage is common, second­
ary to heartworm infestations. The fifth 
stage larva can embolize the terminal
branches of the pulmonary arteries result­
ing in a physical impediment to blood- 
flow. The presence of adults in the 
larger arteries causes endothelial damage 
which ultimately leads to villous prolif­
eration of the intimal lining of the ves­
sel wall. Muscular hypertrophy of the 
tunica media occurs in the smaller ar­
teries. Damage to the vascular endothe­
lium activates platelets and can initiate 
the coagulation cascade resulting in 
thrombus formation and subsequent infarc­
tion of the lungs. The allergic response 
to the heartworms results in a pulmonary 
infiltrate consisting predominantly of 
eosinophils. Many of these pulmonary 
changes result in narrowing of the vascu­
lar lumen which results in pulmonary hy­
pertension, right ventricular hypertrophy 
and rarely right-sided heart failure. 
Several reports of neurological damage 
have been reported following aberrant 
parasite migration to the brain.
Clinical Disease
Any cat that is exposed to a mosquito 
runs the risk of developing heartworm 
disease. Cats ranging in age from 1-17 
years have been reported with the dis­
ease. It is more commonly diagnosed in 
outdoor cats and male cats. This is 
probably due to their increased risk or 
exposure. There is no increased risk in 
cats with feline leukemia virus infec­
tions .
Cats with heartworms can be asymptoma­
tic; they can have a sudden onset of se­
vere signs; or they can have signs of 
chronic nature. The signs seen in an 
acute illness include collapse, dyspnea,
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convulsions, vomiting, diarrhea, and 
blindness. It would be unlikely to see 
all these signs in one animal. Rarely 
will a seemingly healthy cat die sudden­
ly, secondary to pulmonary thromboembol­
ism. Cats with chronic illnesses caused 
by heartworms usually exhibit respiratory 
problems or vomiting. Rarely will the 
same animal exhibit both signs. Respira­
tory signs can include coughing, dyspnea, 
and hemoptysis. The coughing may wax and 
wane and often improves temporarily with 
steroid administration. The vomiting is 
usually sporadic. The vomitus is either 
food or foam and is rarely bile stained. 
Other signs of chronic disease include an­
orexia, lethargy, or neurologic abnormali­
ties. Cats with chronic heartworm disease 
can still die acutely.
Diagnosis
The diagnostic process begins with a 
thorough physical examination. Most cats 
with heartworm disease have no physical 
abnormalities. Some cats will have harsh 
lung sounds while others may have cardiac 
arrythmias or murmurs.
The appropriate diagnostic tests will 
depend on the history and physical examin­
ation findings. The diagnostic plan for a 
chronically vomiting cat will obviously 
differ substantially from that for an 
acutely dyspneic cat. A complete blood 
count (CBC) will reveal a mild nonregener- 
ative anemia and an eosinophilia in one- 
third of all heartworm-positive cats. The 
only common abnormality on a serum chemis­
try panel is a hypergammaglobulinemia. 
Urinalysis is usually normal.
Tests that are more diagnostic of 
heartworm disease include radiographs, 
electrocardiograms (ECG), echocardiograms 
(ECHO), a tracheal wash, a Knotts test, 
and serologic tests. Chest radiographs 
usually show enlargement and blunting of 
the pulmonary arteries which is best vis­
ualized in the caudal lobar arteries using 
the dorsoventral projection. The lung 
parenchyma may show atelectasis, perivas­
cular infiltrates or an alveolar pattern. 
Sometimes the heart will be enlarged.
If the radiographs are suggestive of 
heartworm disease, an angiocardiogram may 
be performed. This technique clearly em­
phasizes the nature and extent of the pul­
monary changes, the type of cardiac en­
largement if present, and may outline 
adult heartworms in the pulmonary arter­
ies. It can also be useful in ruling out 
cardiomyopathy as the cause of cardiomega—
iy.
To further evaluate the heart an elec­
trocardiogram can be performed. With
heartworm disease, it can be normal or it
may confirm the presence of right heart 
enlargement. An echocardiogram can be
useful in assessing cardiac function and 
characterizing cardiac changes. Heart­
worms are sometimes visualized with this 
technique.
If the physical examination and radio­
graphs reveal pulmonary infiltrates a 
tracheal wash may be indicated. Inflamma­
tory cytology is often seen, with eosino­
phils being the predominant cell type.
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3A definitive diagnose of the disease 
requires direct visualization of the mi­
crofilaria in the blood, detection of an­
tibodies directed against the worms, or 
detection of adult cuticular antigens in 
the serum. A Knotts test is used to con­
centrate the microfilaria from a blood 
sample. However, because so many of the 
microfilaria are removed in the cats' 
lungs, only 20% of cats with heartworm 
disease will be diagnosed by this techni­
que.
The most promising tests for the in- 
hospital diagnosis of heartworm disease in 
the cat are ELISA tests. The original 
test for heartworms measures antibodies in 
the serum directed against an adult cuti­
cular antigen. This test is extremely 
sensitive, but false positive results do 
occur. A newer test detects the presence 
of an adult cuticular antigen in the serum 
of an infected animal. This test is 
equally sensitive, but has fewer false 
positive results.
Treatment
The treatment for cats is the same as for 
dogs. The adult worms are killed first 
very toxic to the kidneys and liver of the 
dog, but seems to be well tolerated by the 
cat. Although most cats can be treated 
sucessfully, some cats will experience 
complications resulting from the emboliza­
tion of dead worms and thrombi. This can 
result in coughing, dyspnea, and hemopty­
sis. If the pulmonary damage is very se­
vere, the cat may die. To minimize the 
risk of thromboembolism it is essential 
that the cat be strictly confined to a 
cage for 7-10 days after treatment, and be 
closely observed in a relatively confined 
environment for an additional 2-3 weeks.
Studies in the dog have shown that as­
pirin administration reduces pulmonary 
thromboembolism. Although its use in 
heartworm-positive cats has not been re­
ported, it may be clinically useful. A 
safe dose would be 10 mg/kg every three 
days. Owners should be cautioned that
treatment of the adult worms is not always 
100% effective, and retreatment may be 
necessary. If microfilaria are present, 
as determined by a Knotts test, the cats 
are treated with either dithiazanine sodi­
um or levamisole 4-6 weeks after the 
adults are killed. An ELISA test should 
be repeated 5-7 months after treatment to 
determine if all the adults have been 
killed. Cats can be treated with diethyl- 
carbamazine to prevent heartworm infec­
tion. This decision should be based on 
the incidence of heartworms in your area.
Although heartworm disease in the cat 
is still an uncommon disease, it should be 
considered in cats with a history of 
chronic vomiting or respiratory problems.■
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Since the spring 1985 issue of "Veterinary 
News", which contained guidelines for the 
use of Norden Laboratories’ new feline 
leukemia vaccine (Leukocell®), the Cornell 
Feline Health Center has received numerous 
requests for additional information. Ex­
panded below are the policy guidelines for 
use of Leukocell® in the Veterinary Medi­
cal Teaching Hospital at Cornell Universi­
ty, addressing the most frequently asked 
questions.
1. "Before vaccination or at the time 
of vaccination the cat should be
tested for the feline leukemia vi­
rus.”
We are more firm in this recommendation 
than Norden Labs. If a vaccinated cat of 
unknown FeLV status at the time of vaccin­
ation is subsequently found to be FeLV- 
positive, it would be impossible to deter­
mine whether the cat was viremic prior to 
vaccination, the vaccine induced the vire­
mia, or the vaccine failed to prevent in­
fection by FeLV exposure after vaccina­
tion .
We suggest the ELISA as a prevaccina­
tion screening test for FeLV because it 
can detect cats in the incubation period 
of the infection prior to the bone marrow 
stage of infection and a positive immuno- 
fluorescent test (IFAT). The ELISA will
also pick up those "test-discordant" cats 
which remain persistently ELISA-positive 
but IFAT-negative. We consider a positive 
result on either test to indicate viremia, 
in which case vaccination is of no bene­
fit. Ideally, the test should be done 
prior to the first vaccination. This 
saves the expense of a separate office 
visit simply for the purpose of the pre­
vaccination test. Several ELISA kits now 
enable results to be obtained within one- 
half hour, and a decision as to whether or
Explanation of FeLV
Gary Cockerell,
not to vaccinate can be made during the 
same visit.
ELISA test occasionally can give false 
positive reactions due to operator error 
or slight non-specific reactions. ELISA- 
positive cats should always be rechecked 
in 3-4 weeks, and in our opinion, persis­
tently ELISA-positive cats should be test­
ed by the IFA test before they are con­
demned .
2. "Cats which have the greatest po­
tential for infection should be vac­
cinated (e.g. show cats, shelter 
cats, negative cats going into multi­
ple households, outdoor cats)."
The purpose of this guideline is to re­
serve vaccination for those cats with the 
highest risk of exposure to FeLV, rather 
than to employ Leukocell® as a standard 
immunization similar to vaccines which 
provide protection against other common, 
but more easily transmitted feline infec­
tious diseases. FeLV is not an efficient­
ly transmitted agent, but rather requires 
prolonged and close contact for its spread 
from infected to uninfected cats. There­
fore, for single or even small groups of 
FeLV-negative cats which are maintained in 
isolation from other possibly FeLV- 
positive cats, the risk of FeLV-infection 
is negligible. On the other hand, we 
never can predict when a FeLV-positive 
stray cat will adopt one of these iso­
lated, single cat households. Certainly, 
vaccination under these conditions can do 
no harm, but probably it is an unwise ex­
penditure of the client's money.
3. "A series of three intramuscular 
injections should be given in the 
following intervals: 9 weeks or old­
er; 3 weeks later; and 3 months la­
ter. Thereafter, an annual booster 
to maintain immunity."
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This recommendation is strictly in accor­
dance with the vaccination "windows" given 
by Norden, but is somewhat more specified 
so as to be in synchrony with the primary 
immunization schedule at the VMTH against 
other feline pathogens. Norden indicates 
that simultaneous use of Leukocell® with 
other established feline vaccines and im­
munization regimens does not interfere 
with the resultant immune response. Cats 
become more resistant to FeLV infection 
with age, but annual booster vaccination 
for the life of the cat.
4. "If the initial blood test is 
positive do not vaccinate or discon­
tinue the vaccination program and re­
test in one month. Also do not vac­
cinate cats that are pregnant or 
blood donors."
Any cat that remains FeLV-positive with 
repeated tests conducted at 1 to 3 month 
intervals should not be vaccinated, but 
considered persistently viremic and han­
dled accordingly. The recommendation not 
to vaccinate pregnant queens is based upon 
general principles of immunization rather 
than specific concern related to Leuko­
cell®.
The recommendation not to vaccinate 
blood donors is based totally on present 
theoretical considerations. Since Leuko­
cell® is prepared from antigenic material 
shed from a FeLV-infected feline lympho- 
blastoid cell line in tissue culture, it 
is possible that feline histocompatibility 
anitgens might be present in the vaccine. 
Immunization with these antigens might 
therefore induce allogeneic immune reac­
tivity (or perhaps even be partially re­
sponsible for some of the adverse reac­
tions observed during the primary immuniz­
ation regimen) which could be transferred 
in the blood of a vaccinated donor cat to 
a recipient cat. Until this possibility 
has been investigated it seems more pru­
dent to protect blood donors from FeLV by 
strict isolation and to reconfirm their 
FeLV-negative status by repeated testing, 
rather than by vaccination.
5. "If the second test is negative 
the cat has experienced a transient 
viremia and may now be naturally im­
mune; however, vaccination should in 
initiated or resumed to further 
booster immunity."
Under natural conditions, many FeLV- 
exposed cats experience a transient vire­
mia followed by an immune response that 
eliminates viremia, the cat reverts to 
FeLV-negative status and is thought to be 
FeLV-immune. However, since the actual 
anti-FeLV or anti-FOCMA antibody titers in 
these cats are seldom known, it seems most 
prudent to proceed with immunization and 
boost whatever naturally acquired immunity 
may be present.
6. "If the second FeLV test is posi­
tive, the cat is persistently viremic 
and should be handled accordingly. 
Vaccination of positive cats has no 
detrimental or beneficial effects."
There is no evidence that Leukocell® can 
reverse an established FeLV viremia, or 
alter the clinical course in viremic 
cats. Neither is there evidence that the 
vaccine produces any greater untoward ef­
fects in FeLV-positive than FeLV-negative 
cats, but it is wasteful of client's mon­
ey. Also it may be embarassing to veteri­
narians if owners are not properly in­
formed and a FeLV-positive cat develops a 
FeLV-related disease subsequent to vaccin­
ation.
Other Considerations
Leukocell® is a promising first generation 
vaccine which provides for the first time 
the possibility of preventing FeLV infec-
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tion by any practical means other than en­
vironmental isolation of susceptible 
cats. Approximately 80% of vaccinated 
cats remained healthy after an experimen­
tal challenge with a large dose of viru­
lent FeLV in conjunction with 
corticosteroid-induced immunosuppression. 
Protection, therefore, is not complete. 
This is a more severe challenge than cats 
experience under natural conditions, but 
this does not necessarily equate with an 
expected greater rate of protection in the 
field where cats are exposed to multiple 
small doses of the virus in association 
with other environmental factors. This 
information will be forthcoming in the 
next several years as results from the use 
of the vaccine in natural exposure envi­
ronments become available.
The ability of Leukocell® to prevent 
latent FeLV-negative infections or the ef­
fect of vaccinating latently infected cats 
are unknown. Furthermore, the actual 
clinical significance of latent FeLV in­
fection remains incompletely understood. 
Latent FeLV infections are not detected by 
routine ELISA or IFAT procedures and 
therefore it is certain that some FeLV- 
negative, but latently FeLV-infected cats, 
will be vaccinated.
The vaccine itself will not produce a 
FeLV-positive test, nor does it contain 
infectious FeLV. As reported by Norden 
Laboratories, Leukocell® does produce ad­
verse reactions in about 13% of vaccines. 
Reactions mostly include local pain and 
discomfort at the vaccination site, but 
also occasional transient systemic reac­
tions such as lethargy, fever, anorexia 
and diarrhea. Reports from veterinarians 
indicate that serious, transient adverse 
reactions occur in less than 1% of vaccin­
ated cats, and therefore the clinican must 
be ready to treat these cats promptly as 
indicated. Norden Laboratories are at­
tempting to identify the cause of these 
reactions, and have test kits that they 
will make available to veterinarians to 
skin test reactor cats. If you are inter­
ested in pursuing the cause of the adverse
systemic reaction in a cat following 
Leukocell® vaccination, call Norden Labor­
atories, (402) 475-4541.
Finally, while Leukocell® provides a 
useful aid in reducing the incidence of 
FeLV infection in cats, its use should not 
provide a false sense of security. Pro­
tection is not absolute. Vaccination 
should add to, but not replace, existing 
test and removal or isolation programs for 
FeLV-inf ected cats.B
Dr. Robert Kirk Retires
Dr. Robert W. Kirk 
will retire on 
July 12 from the 
faculty of the New 
York State College 
of Veterinary Med­
icine at Cornell 
University. He 
has held positions 
as professor and 
chairman of small 
animal medicine, 
and director of 
the Veterinary Medical Teaching Hospital. 
He is the author or editor of several 
books, including the world-famous Current 
Veterinary Therapy.
Dr. Kirk has been a participant of the 
Cornell Feline Health Center since its 
founding in 1974. His encouragement and 
support have been greatly appreciated.
A retirement celebration will be held 
on Sunday, July 14 at 5 pm. For informa­
tion and reservations contact:
Office of the Dean
NYS College of Veterinary Medicine
Cornell University
Ithaca, NY 14853
(607) 256-5454
If you would like to contribute materi­
al for a memorabilia book for Dr. and 
Mrs. Kirk, please send items to the above 
address. ■
7Toxoplasmosis: Interpretation of Serological Results
Richard H. Jacobson, M.S., Ph.D.
Based on many telephone conversations with 
practitioners, we find that interpretation 
of serological results for toxoplasmosis 
is poorly understood in terms of its rela­
tionship to the differential diagnosis and 
its zoonotic implications. This apparent­
ly results from a misunderstanding of the 
disease in cats and its epidemiological 
implications.
A positive serological result in cats 
simply means that the cat has been previ­
ously infected with the agent, Toxoplasma 
gondii. In the absence of clinical mani­
festations suggestive of toxoplasmosis, it 
has little significance in disease diagno­
sis. Although there is a relatively high 
prevalence rate of this infection in cat 
populations, overt clinical disease asso­
ciated with it is fairly uncommon. The 
parasite is very well adapted to its host 
and often can remain viable in the host's 
tissues for years without causing clinical 
signs.
Indoor cats generally are serologically 
negative unless they are habitually fed 
raw meat products. Outdoor cats, includ­
ing those which are allowed outside for 
brief intervals, have the highest preva­
lence rates of toxoplasmosis. Following 
ingestion of an infectious meal, oocyst 
production begins in several days and con­
tinues for 14-21 days with millions of 
oocysts being shed in the feces. After 
this period, oocyst shedding usually 
ceases commensurate with the appearance of 
serum antibody. Generally, however, the 
cat does not shed oocysts after its immune 
response is activated. Therefore, even 
though a cat may be serologically positive 
for extended periods, it generally will 
not be shedding oocysts.
Recrudescence of oocyst shedding is 
relatively uncommon. It has been experi­
mentally induced, although at substantial­
ly reduced levels and for abbreviated in­
tervals, following immunosuppressive ther­
apy or subsequent to immunosuppressive in­
fections. If a serologically positive cat 
ingests another infectious meal, oocyst 
shedding is generally not observed. If in 
the rare event it does occur, only a few 
oocysts are shed for a short time.
Elevated antibody levels in chronically 
infected cats are usually persistent. 
When the differential diagnosis for a 
clinically ill cat includes toxoplasmosis 
and the cat is serologically positive for 
toxoplasmosis, clincians often conclude 
that toxo is the problem. Usually T. 
gondii is not very pathogenic in cats. It 
is highly prevalent in some cat popula­
tions, and may have been present in the 
cat a long time prior to the current con­
dition. Hence, the current titer may be 
incidental to the clinical observations.
Alternatively, a positive toxo titer 
may indeed support the clinical findings, 
particularly when the titer is very high. 
This is suggestive of increased stimula­
tion of the immune system either by a re­
cently acquired infection or by the per­
sistent release of zoites from the pseudo­
cysts in tissues harboring large numbers 
of organisms. Periodically, however, we 
see high titered cats which are clinically 
normal. Therefore, the level of anti-toxo 
antibody in cats is not necessarily di­
rectly related to disease.
Test Kits
Recently, test kits for detecting antibody 
to T. gondii in the cat's serum have be­
come available. Generally, these only in­
dicate whether the cat is serologically 
positive or negative (qualitative result)
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and do not provide a titer (quantitative 
result). If one is screening cats for the 
presence of anti-toxo antibody, possibly 
to assess the infection status of the cat 
for a client, then the tests can provide 
useful information. These results can be 
misleading when confirming a clinical di­
agnosis of toxoplasmosis. A positive test 
may be due to antibody production from 
previous exposure, but is unrelated to the 
current problem. The serological confir­
mation of clinical toxoplasmosis in cats 
requires quantitative results on paired 
samples.
With the current increase in serologi­
cal testing systems it is essential that 
clinicians demand an interpretation of 
serological results for a given system. 
This is especially important because there 
are no officially accepted standards for 
test validation. Only when interpretative 
information includes many of the aforemen­
tioned factors, then an informed interpre­
tation can be made which will lend support 
to the differential diagnosis.
Conclusion
A serologically positive cat generally is 
not shedding oocysts and rarely would be a 
source of infection to humans. Under cer­
tain immunosuppressive conditions, oocysts 
may appear in the feces. Therefore, we 
recommend that pregnant women take precau­
tions when handling cat litter pans, even 
though transmission is remote.
Don't overinterpret a positive serolo­
gical result in which toxoplasmosis is in­
cluded in the differential diagnosis. Re­
member, cats with chronic T. gondii infec­
tion may have positive titers for years 
even though no clinical manifestations of 
the disease may be evident. Thus, titers 
in clinically ill animals may be irrele­
vant in the differential diagnosis.
Quantitative results are the most use­
ful in assessing the significance of ser­
ology for toxoplasmosis. Although some 
useful information can be obtained from 
qualitative tests, their usefulness in un­
derstanding the role of T. gondii in a 
differential diagnosis is reduced due to 
the relatively high prevalence of the in­
fection in certain cat populations. ■
Richard H. Jacobson, M.S, Ph.D., is an 
associate professor of immunology and par­
asitology with appointments in the Diag­
nostic Laboratory and Department of Pre­
ventive Medicine, New York State College 
of Veterinary Medicine, Cornell Universi­
ty.
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